Successful treatment of Paecilomyces lilacinus endophthalmitis with voriconazole.
Paecilomyces lilacinus is a rare cause of endophthalmitis and there are few reports of it in the literature. Herein we report a patient with P. lilacinus endophthalmitis who was treated with the new triazole, voriconazole, for 4 months, with a good clinical evolution. This treatment appears to be a valuable new therapeutic option but requires further clinical confirmation.
Garbino
Jorge
J
Division of Infectious Diseases, University of Geneva Hospitals, Switzerland. jorge.garbino@hcuge.ch
Ondrusova
Adriana
A
Baglivo
Edoardo
E
Lew
Daniel
D
Bouchuiguir-Wafa
Kathum
K
Rohner
Peter
P
Baligvo
Edoardo
E
D000293:Adolescent; D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000627:therapeutic use*; D009877:Endophthalmitis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy*; D010143:Paecilomyces / Q000302:isolation & purification*; D011743:Pyrimidines / Q000627:therapeutic use*; D014230:Triazoles / Q000627:therapeutic use*; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole